Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia

• Published in: Gene 2019-02, Vol.686, p.85-91
• Main Authors: Chandran, Ramachandran Krishna, Geetha, Narayanan, Sakthivel, Kunnathur Murugesan, Aswathy, Chandran Geetha, Gopinath, Preethi, Raj, Thampirajan Vimaladevi Akhila, Priya, Geetha, Nair, Jagathnath Krishna Kumarapillai Mohanan, Sreedharan, Hariharan
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; BCR-ABL1 fusion gene; Chromosome Banding; Chronic myelogenous leukemia; Female; Fluorescence in situ hybridization; Fusion Proteins, bcr-abl - genetics; Fusion Proteins, bcr-abl - metabolism; Gene Amplification; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy; Male; Middle Aged; Philadelphia Chromosome
• ISSN: 0378-1119; 1879-0038
• DOI: 10.1016/j.gene.2018.11.005

Identification of BCR-ABL1 fusion gene amplification status is critically important in the effective management of chronic myelogenous leukemia (CML) patients. Earlier reports suggested that overexpression of BCR-ABL1 either through amplification of BCR-ABL1 fusion gene or by the up regulation of BCR-ABL1 transcript level might be an early phenomenon in the establishment of IM resistance and disease evolution in CML. In the current study, we performed dual color dual fusion locus specific BCR/ABL1 FISH analysis along with karyotype analysis using GTG banding (G-banding using trypsin and Giemsa) technique in 489 patients with different clinical stages of CML at diagnosis or during the course of the disease to unravel the spectrum of BCR-ABL1 fusion gene amplification status. Among the study group analyzed, it was found that prevalence of occurrence of BCR-ABL1 fusion gene amplification was significantly higher in advanced stages of disease and in IM resistant CML-CP patients when compared to initial stage of disease, de novo CML-CP. Cytogenetic and metaphase FISH characterization on our study samples revealed that BCR-ABL1 fusion gene amplification was occurred through the formation of extra copies Ph chromosomes and isoderived Ph chromosomes. Current study suggests that unrestrained activity of BCR-ABL1 played a vital role in resistance to targeted therapy and disease evolution in CML. In our study population, patients in progressive stage CML and in IM resistant CP with multiple copies of BCR-ABL1 fusion gene displayed a poor response to targeted treatment with IM. Hence, the early identification of BCR-ABL1 fusion gene amplification using FISH technique will lead to improved interventions and outcome in future CML patients. •The impact of BCR-ABL1 fusion gene amplification during disease progression of CML.•Genomic amplification of BCR-ABL1 fusion gene could act as a prognostic markers in CML.•Importance of performing BCR/ABL1 FISH analysis in CML patients at the time of initial diagnosis for effective clinical management